Author Information

Techniques and Innovations in Gastrointestinal Endoscopy (TIGE) publishes articles pertaining to gastrointestinal diseases with a particular focus on innovation in gastrointestinal endoscopy. TIGE publishes original research, expert reviews, and other article types (details below). Manuscripts must be prepared in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" developed by the International Committee of Medical Journal Editors (http://www.icmje.org). TIGE is a member of the Committee on Publication Ethics (COPE) (https://publicationethics.org/).

TIGE is indexed in Embase, Scopus, Clarivate Emerging Source Citation Index, and Reactions Weekly.

TIGE strongly encourages the submission of papers on a breadth of clinical topics in gastroenterology and hepatology, especially randomized controlled trials, high-quality observational including epidemiological and outcomes studies, and novel case series. TIGE is interested in multiple facets of clinical and translational endoscopic studies including treatment, prevention, screening, and diagnosis. High-quality systematic and meta-analyses are also welcome and will be highlighted in a special section. Publication priority will be determined by factors such as novelty, impact upon clinical practice, strength of the experimental design, and insight into future practices.

TIGE is currently published on a quarterly basis.

Ethical Standards
Diversity, Equity, and Inclusion (DEI) Statement
Conflict of Interest Policy
Plagiarism, Duplicate Submission/Publication Policy
Image Manipulation Policy
Open Access Policies
Information about Article Types
Submission Checklist
Data Transparency
Reporting Clinical Trials
Manuscript Processing and Review
Appeals Policy
Publication
Commercial Sponsorships/Supplements
Editorial Office


ETHICAL STANDARDS
TIGE strongly discourages the submission of more than one article dealing with related aspects of the same study. In almost all instances, a single study is best reported in a single, unique paper.

The Journal editors consider research/publication misconduct to be a serious breach of ethics and will act as necessary to address such misconduct, which includes submission or publication of information that:
  • Is intentionally erroneous,
  • Has been published elsewhere by a different author without acknowledgment (plagiarism),
  • Has been published elsewhere by the same author without acknowledgment (duplicate publication), or
  • Is subsequently published elsewhere by the same author without acknowledgment, attribution, or permission from Elsevier, as holder of the copyright, to reprint or adapt the material


Each author who submits a manuscript to TIGE must attest to several author statements in the manuscript management system, thereby assigning copyright of the manuscript to Elsevier and affirming authorship responsibility, manuscript originality, IRB/Animal Care Committee approval, role of study sponsor, financial disclosures, and funding sources.

Breaches of TIGE's ethical standards may result in proscribed submission for all authors of the concerned manuscript and, when appropriate, notification of the authors' institutions. All authors are fully responsible for the content of the manuscript.

The publication of abstracts is not considered duplicate publication but should be disclosed in the cover letter accompanying the manuscript submission.

Authorship
Each author must have participated sufficiently in the work to take public responsibility for the content of the paper and must approve of the final version of the manuscript. Authorship should be based on substantive contributions to each of the following:
  • Conception and design of the study;
  • Generation, collection, assembly, analysis and/or interpretation of data;
  • Drafting or revision of the manuscript;
  • Approval of the final version of the manuscript.



DIVERSITY, EQUITY, AND INCLUSION (DEI) STATEMENT
TIGE envisions a scientific publishing enterprise that is diverse, equitable, and inclusive (DEI). To achieve that desired state, we will develop and implement processes, practices, and policies that will eliminate the barriers for groups underrepresented in the scientific-development continuum. Additionally, we will publish content that reflects our commitment to effect positive change around DEI in medicine, with an emphasis on advancing equity in the research enterprise.


CONFLICT OF INTEREST POLICY
A. Potential Conflicts of Interest
The following are examples of COI that may occur with editors, authors (including invited authors), and reviewers. Interactions considered pertinent are from the start of the research activity in a specific program until such time that a submission is anticipated to be published or one year from submission date, whichever is longer.
  • a. Editors: Editors who make final decisions about manuscripts must have no personal, professional, or financial involvement in any of the issues they might judge. Examples of personal involvement with an author include former student, fellow, mentor, or relative. Examples of professional involvement include academic rivalry, being from the same institution or research group as the author, evaluating a manuscript submitted by a member of the board of editors, or collaborating (e.g., co-authoring research article or grant) with an author. Examples of financial involvement include employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties with an entity (or competing entity) discussed in the manuscript.
    It is a COI for editors of the AGA Institute journals to hold a position of editorial responsibility for a competing publication. The Ethics Committee reviews disclosure statements submitted by editors and notifies either/both the Secretary/Treasurer and editor of any potential conflicts. The procedures contained in Section C of the "AGA/AGA Institute Policy on Disclosure of Potential Conflict of Interest" apply if a conflict is found to exist.
  • b. Authors: COI for an author may arise if there exists a financial arrangement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties) with a company whose product figures prominently in the submitted manuscript or with a company that makes a competing product.
  • c. Reviewers: COI for reviewers exist when they have had an ongoing collaboration, original publications, or grants with the authors within the previous two years, except when part of a multicenter group from a different site; are from the same institution as the authors; or have any financial arrangements (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties) with a company whose product figures prominently in the submitted manuscript or with a company that makes a competing product.


B. Process
Potential COI are to be disclosed at the beginning of the peer-review process
  • a. Editors: An associate editor having COI with a submitted manuscript must recuse himself from handling the manuscript and request that the manuscript be reassigned. The editor-in-chief having COI with a submitted manuscript must assign review to one of an associate or guest editor for handling.
  • b. Authors: The senior or corresponding author assumes full responsibility for supplying the following information on the title page at manuscript submission:
    1. For each author, disclosure of any financial arrangement with any company whose product figures prominently in the submitted manuscript or that makes a competing product; or a statement for each author that there is no conflict to disclose.
    2. A disclosure of all funding sources supporting the work and all institutional or corporate affiliations.
    3. A list of individuals who provided writing assistance for the manuscript and the source of funds that supported this assistance.
    In addition, at manuscript submission, each author must attest to several author statements in the manuscript management system, thereby assigning copyright of the manuscript to Elsevier and affirming authorship responsibility, manuscript originality, IRB/Animal Care Committee approval, role of study sponsor, financial disclosures, and funding sources.
    Based on the information provided, the editors will determine whether COI exists and decide to either a) reject the manuscript or b) publish the manuscript with the COI disclosed.
  • c. Reviewers: When invited, reviewers must decline to review a manuscript if a potential COI exists. After review, all reviewers must agree to and initial one of the following statements, which appear in the journals' manuscript tracking system:
    1. I, the undersigned Reviewer, certify that I have not had an ongoing collaboration, original publication, or grant with the authors within the previous two years, except in the case of being a part of a multicenter group from a different site, nor am I from the same institution as the authors. I also certify that I do not have any financial arrangements (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received, and royalties) with a company whose product figures prominently in the submitted manuscript or with a company that makes a competing product.
    2. I have listed any potential conflicts on interest in the Comments to Editors field.


If the reviewer discloses a potential COI after the review, the handling associate editor decides if the review should still be used to judge the manuscript.

C. Sanctions
Should an editor, author, or reviewer fail to disclose a potential COI and this is discovered after publication, the following sanctions may be applied according to the severity of the infraction
  • a. Editors:
    1. A letter of reprimand and warning as to future conduct from the editor, in the case of an associate editor, or from the Chair of the Publications Committee, in the case of the editor.
    2. Dismissal from the position.
  • b. Authors:
    1. A letter from the editor of explanation and education where there appears to be a genuine misunderstanding of principles.
    2. A letter from the editor of reprimand and warning as to future conduct.
    3. A letter from the editor to the author's institution or funding body.
    4. Publication of a notice detailing the author's failure to disclose the COI.
    5. Publication of an editorial detailing the full details of the misconduct.
    6. Refusal to accept future submissions from the author on a sliding scale of one-to-five years.
    7. Formal retraction or withdrawal of the paper from the scientific literature.
    8. Reporting the case to the Office of Research Integrity (ORI).
  • c. Reviewers:
    1. A letter from the editor of explanation and education where there appears to be a genuine misunderstanding of principles
    2. A letter from the editor of reprimand and warning as to future conduct.
    3. A letter from the editor to the reviewer's institution.
    4. Refusal to allow the individual to review for the journal on a sliding scale of one-to-five years


This policy was developed in accordance with the guidelines set forth by COPE and ICMJE.

PLAGIARISM, DUPLICATE SUBMISSION/PUBLICATION POLICY

A. Definitions
  • a. Plagiarism: Unreferenced use of published and unpublished ideas. It may occur at any stage of planning, research, writing, or publication and applies to print and electronic versions.
  • b. Duplicate Submission/Publication: Occurs when two or more papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.


B. Sanctions
Should plagiarism or duplicate submission/publication be identified, the journal editors will apply the following sanctions according to the severity of the infraction. They will apply sanctions to individual authors depending on their type of involvement with the article, as provided at the time of submission on the title page.
  • a. A letter of explanation from the journal editors to the authors where there appears to be a genuine misunderstanding of principles.
  • b. A letter of reprimand from the journal editors as to future conduct
  • c. A formal letter from the journal editors to the author's institution, employer, or funding body.
  • d. Publication of a notice or editorial in journal.
  • e. Refusal to accept submissions from the author for a range of one-to-five years.
  • f. Formal withdrawal or retraction of paper from the scientific literature.
  • g. Journal editors report the case to Office of Research Integrity, which promotes integrity in biomedical and behavioral research supported by the U.S. Public Health Service; monitors institutional investigations of research misconduct; and facilitates the responsible conduct of research through educational, preventive, and regulatory activities.


This policy was developed in accordance with the guidelines set forth by COPE and ICMJE.

IMAGE MANIPULATION POLICY

A. Definition*
Image manipulation is the misrepresentation of data by selectively altering portions of an image. The expectations for how images should be ethically handled are:
  • a. No specific feature within an image may be enhanced, obscured, moved, removed or introduced.
  • b. The grouping of images from different parts of the same gel, or from different gels, fields or exposures must be made explicit by the arrangement of the figure (e.g., using dividing lines) and in the text of the figure legend.
  • c. Adjustments of brightness, contrast or color balance are acceptable if they are applied to every pixel in the image and as long as they do not obscure, eliminate or misrepresent any information present in the original, including backgrounds. Non-linear adjustments (e.g., changes to gamma settings) must be disclosed in the figure legend.
*Language used with permission from The Journal of Cell Biology.

B. Process
The journals' graphics staff will screen images at random during the submission process and will review images that editors, reviewers or readers suspect have been manipulated. If manipulation is suspected, the staff and editors will initiate an investigation with the authors and possibly their institutions.

C. Sanctions
Should image manipulation be verified before or after publication of an article, one of the below sanctions will be applied, based on the severity of the infraction. The journal editor-in-chief and board of editors will determine, on a case-by-case basis, the severity of the infraction and corresponding sanction. Sanctions will be applied to individual authors depending on their type of involvement with the article, as provided at the time of submission on the title page.
  • A letter of explanation from the journal editors to the authors where there appears to be a genuine misunderstanding of principles.
  • A letter of reprimand from the journal editors as to future conduct.
  • A formal letter from the journal editors to the author's institution or employer.
  • Rejection or withdrawal of manuscript acceptance.
  • Publication of a correction or editorial.
  • Retraction of the published article.
  • Refusal to accept submissions from the author for a range of one-to-five years. For particularly egregious cases or series of cases, a life-time ban may be considered.


The AGA reserves the right, on a case-by-case basis, to report particularly egregious cases to the relevant funding bodies.

This policy was developed in accordance with the guidelines set forth by COPE.

OPEN ACCESS POLICIES
This journal offers authors a choice in publishing their research:

Subscription
  • Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
  • No open access publication fee payable by authors.
  • The Author is entitled to post the accepted manuscript in their institution's repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal is 12 months.


Gold Open Access
  • Articles are freely available to both subscribers and the wider public with permitted reuse.
  • A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.
  • The gold open access publication fee for TIGE is USD 2,500.00 excluding taxes.


Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

Creative Commons Attribution-Non Commercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. The embargo period for TIGE is 12 months.

Compliance With Funders Open Access Policies
TIGE's publishing partner, Elsevier, has established agreements and developed policies to allow authors who publish in Elsevier journals to comply with manuscript archiving requirements of various funding bodies (for example, the National Institutes of Health, Wellcome Trust, and Research Councils UK), as specified as conditions of researcher grant awards. For a full list of funding bodies with which Elsevier has agreements, go to http://www.elsevier.com/about/publishing-guidelines/policies/funding-body-agreements. These agreements and policies enable authors to comply with their funding body's archiving policy without having to violate their publishing agreements with TIGE. The agreements and policies are intended to support the needs of the Journals authors, editors, and society publishing partners, and to protect the quality and integrity of the peer-review process.

Author-Sponsored Articles
TIGE offers authors the option to sponsor immediate open access to their articles online at www.Journals.elsevier.com/techniques-in-gastrointestinal-endoscopy and www.sciencedirect.com. Authors can elect to sponsor their article only after receiving notification that their article has been accepted for publication in TIGE. The charge for article sponsorship is $2,500.00 which is used to offset publishing costs of typesetting, tagging, and indexing of articles, hosting articles on dedicated servers, supporting sales and marketing costs to ensure global dissemination via www.Journals.elsevier.com/techniques-in-gastrointestinal-endoscopy and www.sciencedirect.com, and permanently preserving the published journal article. The fee excludes taxes. Authors who have had their article accepted and who wish to sponsor their article to make it immediately freely available should complete and submit the sponsored article order form. You will need your Elsevier Production Article Number to complete the form. You will receive this number via email once your accepted manuscript has been received and processed by Elsevier.

Manuscript Posting
Authors of articles published in TIGE may voluntarily post their accepted manuscripts to personal websites or institutional repositories immediately upon acceptance.

INFORMATION ABOUT ARTICLE TYPES

Original Articles
Original Articles are full-length reports of original research related to digestive conditions focused on applications of gastrointestinal endoscopy. Articles cover topics relevant to clinical studies in these areas of interest. To be published, the work presented in the manuscript must be original; on occasion, confirmatory studies of timely and important observations will also be acceptable. In addition, other considerations for evaluating the acceptability of a submitted manuscript include its importance, the soundness of the experimental design, the validity of the methods, the appropriateness of the conclusions, and the quality of presentation.

Original articles submitted to TIGE cannot exceed 4,000 words including main text and table/figure legends. Articles are limited to 50 references. No more than 6 figures and/or tables are permitted, though more may be included online only supplemental material. Each figure may have up to 6 panels (labeled A-F). Videos edited to demonstrate salient features of the technique are encouraged. Videos in aggregate (i.e., across main content and supplemental material) may not exceed 6 per original article. Individual videos may not exceed 3 minutes and must be both edited and narrated. The editor reserves the right to publish excessively long tables as online-only material. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: only Microsoft Word documents will be accepted.
  • Title page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Word count: 4,000 words (includes main text and table/figure legends only).
  • Abstract: 250 words, structured as follows: background and aims; methods; results; conclusion; 4-5 keywords.
  • Tables/Figures: 6 tables (no panels) and/or figures (up to 6 panels) total.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
  • Videos: 6 videos per submission, limited to 3 minutes each, and must be edited and narrated.
  • References: Limited to 50
    • Format: Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92:1174-1180 (list 3 authors followed by et al).
  • Randomized Controlled Trials: Provide CONSORT checklist and patient flowchart as supplemental attachments.
  • Clinical Trials:
    • Provide the clinical trial registry website and trial number at the end of the "conclusions" section of the abstract.
    • Include a statement in the "methods" section of the manuscript affirming that "all authors had access to the study data and reviewed and approved the final manuscript.
    • Include the clinical trial protocol in English as a supplemental attachment.
  • Revised manuscripts:
    • What You Need to Know: This note will appear as a box on the second page of the published version of each article, containing summarizations about your study under the following 3 headings: Background, Findings, and Implications for patient care. Please provide 25-30 words under each of these 3 headings that very briefly summarize your study in relation to each category.


Research Letters
Research Letters are concise and smaller scientific reports of original research studies. The format is as follows: no abstract, article text must not exceed 1,000 words (main text only), 10 references maximum, and up to 1 table, figure, or video. Each figure may have up to 6 panels (labeled A-F). If needed, 1-2 additional figures, tables, or videos for describing results, and up to an additional 500 words of text for describing methods may be included as supplementary material. The text cannot be used to provide additional results or discussion. Videos edited to demonstrate salient features of the technique are encouraged. Individual videos may not exceed 3 minutes and must be both edited and narrated. These reports are not the same as a Letter to the Editor and must not duplicate other material published or submitted for publication. Research Letters may not include any section headers, and all article titles should be declarative. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: Only Microsoft Word documents will be accepted.
    • Submissions should not include any section headers
  • Title Page: title; authors' names (limit of 6); authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
    • Author limit: Authors can include a seventh "Corporate Authorship" in the author listing. The Corporate Author must be named (for example "The National Cancer Institute's PROSPR Consortium" or "The Inflammatory Bowel Disease Working Group") and can include as many individuals as needed. These individuals will be searchable and discoverable in the final version of the article on PubMed as authors of the paper and will be listed in the "Acknowledgement" section of the article as contributors. On the title page of the manuscript, please list out in a distinct "Contributors" section all of the individuals to be included in the Corporate Authorship, including each individual's affiliation.
  • Word Count: 1,000 words (includes main text only).
    • 500 additional words of text for describing methods may be included as supplementary material.
  • Abstract: No abstract.
  • Tables/Figures/Videos: May include up to 1 table (no panels), figure (up to 6 panels), or video.
    • 1-2 additional figures, tables, or videos for describing results may be included as supplemental material.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
    • Videos are limited to 3 minutes each and must be edited and narrated.
  • References: Limited to 10.
    • Format: Jones RS, et al. Gastroenterology 2011; 2: 373-380 (only the first author is listed, unless manuscripts with joint first authors are cited, and article title is not included).
  • These reports are not the same as a Letter to the Editor and must not duplicate other material published or submitted for publication.


Innovation in Endoscopy
Innovation in Endoscopy articles report experiences with new developments in gastrointestinal endoscopy. Articles should not exceed 2,000 words (main text only) with no more than 25 references and 2 tables or figures. Each figure may have up to 6 panels (labeled A-F). No abstract is required. The report should contain truly novel information. Articles describing only a minor change to an existing procedure are discouraged. Articles may pertain to other aspects of endoscopy (e.g., sedation, patient workflow, workplace innovations) in addition to innovations in procedural technique. Videos edited to demonstrate salient features of the technique are encouraged. Videos in aggregate (i.e., across main content and supplemental material) may not exceed 6 per article. Individual videos may not exceed 3 minutes and must be both edited and narrated. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: Only Microsoft Word documents will be accepted.
  • Title Page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Word Count: 2,000 words (includes main text only).
  • Abstract: No abstract.
  • Tables/Figures: May include up to 2 tables (no panels) or figures (up to six panels).
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
  • Videos: 6 videos per submission, limited to 3 minutes each, and must be edited and narrated.
  • References: Limited to 25.
    • Format: Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92:1174-1180 (list 3 authors followed by et al).


Case Series
Case Series articles analyze a series of four or more related cases, described in no more than 1,200 words (main text only) and 15 references, with no abstract. Individual case reports will not be considered. A total of 2 figures are allowed. Each image may have up to 6 panels (labeled A-F). Videos edited to demonstrate salient features of the technique are encouraged. Videos in aggregate (i.e., across main content and supplemental material) may not exceed 6 per article. Individual videos may not exceed 3 minutes and must be both edited and narrated. Submissions that include video will be given priority. Authors must follow the CARE guidelines found at https://www.care-statement.org/. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: Only Microsoft Word documents will be accepted.
  • Title Page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Word Count: 1,200 words (includes main text only).
  • Abstract: No abstract.
  • Tables/Figures: May include up to 2 figures (6 panels).
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
  • Videos: 6 videos per submission, limited to 3 minutes each, and must be edited and narrated.
  • References: Limited to 15.
    • Format: Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92:1174-1180 (list 3 authors followed by et al).


Letters to the Editor
Letters to the Editor offer opinions on papers published in TIGE. Such correspondence is evaluated only for articles published within one month of submission of the letter (e.g., for the July 2019 issue, letters submitted after August 31, 2019 will not be considered). Those letters deemed of interest to the Journal are sent to the authors of the original article for a response; the authors are given 2 weeks to reply. A decision will then be made whether to publish the letter with or without its reply.

Letter to the Editor submissions must not exceed 500 words (main text only), with no more than 8 references. Original or unpublished data will not be considered. The correspondence and the reply cannot include more than 3 authors each. All letters become the property of TIGE and are subject to editing by the Journal. Letters are selected based on their relevance and originality. TIGE will not publish letters commenting on manuscripts for which letters have already been published. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: Only Microsoft Word documents will be accepted.
  • Title Page: title; authors' names (limit of 3); authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Word Count: 500 words (includes main text only).
  • Abstract: No abstract.
  • Tables/Figures: Not permitted
  • References: Limited to 8.
    • Format: Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92:1174-1180 (list 3 authors followed by et al).
  • Must reference an article in press or an article appearing in the current issue at time of submission. (e.g., a response to a July article must be submitted by the end of August).


Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analyses are manuscripts that feature an organized and detailed review of the scientific literature about a topic relating to gastrointestinal endoscopy. This section is peer-reviewed and acceptance for publication is not guaranteed. The length must not exceed 6,000 words (including main text, references, and table/figure legends) and a maximum of 6 tables and/or figures. Each figure may have up to 6 panels (labeled A-F). For meta-analyses of randomized, controlled trials, authors must provide a CONSORT checklist at manuscript submission and follow the PRISMA reporting guidelines found at http://www.prisma-statement.org/. For meta-analyses of observational studies, authors must follow the MOOSE reporting guidelines found here: http://www.editorialmanager.com/jognn/account/MOOSE.pdf. As TIGE does not publish animal research, guidelines such as ARRIVE and Care and Use of Laboratory Animals are not required. Your manuscript will be returned to you if it does not meet these criteria.
  • Manuscript: only Microsoft Word documents will be accepted.
  • Title page: title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors).
  • Word count: 6,000 words (includes main text and table/figure legends only).
  • Abstract: 250 words, structured as follows: background and aims; methods; results; conclusion; 4-5 keywords.
  • Tables/Figures: 6 tables (no panels) and/or figures (up to 6 panels) total.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 PPI resolution).
  • References:
    • Format: Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987; 92:1174-1180 (list 3 authors followed by et al).
  • Randomized Controlled Trials: Provide CONSORT checklist as supplemental attachment.
  • Revised manuscripts:
    • What You Need to Know: This note will appear as a box on the second page of the published version of each article, containing summarizations about your study under the following 3 headings: Background, Findings, and Implications for patient care. Please provide 25-30 words under each of these 3 headings that very briefly summarize your study in relation to each category.


Narrative Reviews
Narrative Reviews provide comprehensive overviews of clinical conditions and gastrointestinal endoscopic procedures to TIGE's readership.
  • Manuscript: only Microsoft Word documents will be accepted.
  • Title page: Title; authors' names; authors' institutions; corresponding author contact information; conflict of interest statement (for all authors); description of how each author contributed to the manuscript; statement if article received funding.
  • Word count: Maximum of 6,000 words (includes main text, references, and table/figure legends).
  • Abstract: Maximum of 250 words, unstructured; 4-5 keywords.
  • References: Limited to 150.
  • Tables/figures: Maximum of 6 tables (no panels) and/or figures.
    • Please submit figures as separate attachments in JPEG, TIFF, EPS, or PDF formats (300 ppi resolution).
    • Additional tables/figures may be included as supplementary items.
    • Please clearly label file names of tables, figures, and supplementary materials (eg, Table 1.docx; Figure 1.jpg; Supplementary Figure 1.tif).
  • Revised manuscripts:
    • What You Need to Know: This note will appear as a box on the second page of the published version of each article, containing summarizations about your study under the following 3 headings: Background, Findings, and Implications for patient care. Please provide 25-30 words under each of these 3 headings that very briefly summarize your study in relation to each category.


SUBMISSION CHECKLIST
All manuscripts should be typed in 12-point font size and double-spaced and should contain the following sections in the order given below. All manuscripts submitted to TIGE are made available for online review. Authors should submit their manuscripts, with figures and tables, electronically via our website, https://www.editorialmanager.com/ytgie. Complete instructions for online submission are located on the website.

Corresponding Author Duties
When submitting a manuscript, the corresponding author should be prepared to complete the following steps:
  • Have an account on https://www.editorialmanager.com/ytgie with a current email address
  • Upload your manuscript files and provide related information such as keywords and classifications relevant to your manuscript's focus area.
  • You may be prompted to propose suggested reviewers, and/or note opposed reviewers for consideration by the Board of Editors. Please note the Board of Editors is not obligated to follow your suggestions.
  • You will answer several questions regarding the composition of your manuscript, and you will attest to statements certifying the validity of the data, funding sources, and intellectual content. You will also assign Elsevier copyright for your manuscript pursuant to acceptance. Any co-authors will confirm their agreement with these statements when they verify their co-authorship.
  • Co-author names, academic degrees, and email addresses are required and must be added to the Editorial Manager system separate from inclusion within the Word document file of your manuscript. ORCID numbers may also be included for you and/or your co-authors, if applicable.
  • The corresponding author will need to respond promptly to all correspondence related to your submission, including requests from the editorial office regarding changes to comply with article type guidelines (if applicable). If the manuscript is accepted, the corresponding author will receive the proof from our publisher and must supply all edits within 48 hours.


Cover Letter
TIGE strongly encourages authors to suggest three to four referees (include their e-mail address, phone, and fax numbers) and the Associate Editor they believe best qualified to review their paper. Authors may also list a non-preferred Associate Editor and non-preferred referees, but the ultimate selection of an Associate Editor and referees is at the sole discretion of the Editor and Associate Editor, respectively. State reasons for deviations, if any, from standard format and clarify any potential conflicts related to the exclusive nature of the publication.

Title Page
Title--Use no abbreviations. Limit: 120 characters including spaces. Must state the main finding of the study.
Short Title--Limit: 45 characters with spaces.
Authors--Include first names of all authors and name and full location of department and institution where work was performed.
Grant Support--List grant support and other assistance.
Abbreviations--List abbreviations alphabetically. (Note: In general, the use of abbreviations is discouraged.)
Correspondence--Provide name, complete address, e-mail address, telephone number, and fax number of corresponding author.
Disclosures--All authors must disclose any potential conflicts (financial, professional, or personal) that are relevant to the manuscript. If the author(s) has nothing to disclose, this must be stated.
Writing Assistance--The names and funding source for individuals who provided writing assistance must be listed.
Author Contributions--This information no longer needs to be included on the Title Page. Instead, the Corresponding Author will select from a list of roles for each co-author from CRediT Taxonomy. Detailed instructions can be found at https://www.editorialmanager.com/ytgie when submitting a manuscript.
We encourage following the SAGER guidelines for sex and gender reporting. Regarding the title page, if only one sex is included in the study, or if the results of the study are to be applied to only one sex or gender, the title and the abstract should specify the sex of animals or any cells, tissues and other material derived from these and the sex and gender of human participants.


Abstract
Abbreviations must be spelled out at least once. Do not use footnotes or references. Structured abstracts should be 250 words or less and include the following sections:

Background and Aims: Provide one-to-two sentences of background information to indicate why the study is interesting and important. Provide one sentence to state the main question addressed by the article.

Methods: Methods should include information on the following aspects of study design, when applicable.
  • Design--describe the basic study design, e.g., randomized controlled trial, cross sectional study, cohort study, case series, survey, etc.
  • Setting--specify whether the study was conducted in a primary or tertiary care setting, in an ambulatory care clinic or hospital, in the general community, etc.
  • Participants--indicate the number of study subjects, how they were selected, what key features were included. What data were collected?
  • Intervention--report the method of administration and duration of the intervention. Describe control groups and what methods were used to analyze the data.
  • Describe main outcome measures


For studies that are quality improvement (QI) related, authors must include a statement about IRB review. Authors must include one of the two statements: 1) This study received IRB approval, and include protocol number; or 2) This study was exempt from IRB review after institutional IRB review.

Results: Describe the main findings of the study, including confidence intervals or P values. Report the absolute values and risk differences so that readers can determine the absolute, as well as the relative, impact of the results. Please be consistent in reporting either number or percentage values.

Conclusions: State conclusions that are directly supported by the evidence and the implications of the findings. For clinical trials, state the clinical trial registration web site and number (e.g., ClinicalTrials.gov, Number NCT002209456).

Keywords
Include three-to-four keywords associated with your manuscript, separated by semicolons (e.g., active vitamin D; parathyroid hormone-related peptide; hypercalcemia; bone resorption).
    Please also consider including some of the keywords on DEI topics, noted below. They will not count toward the overall keyword limit.
  • URM/URIM (underrepresented minorities and race and ethnic categories such as: Black/African-American; Hispanic/Latinx; Native American/Indigenous/American Indian)
  • AAPI (Asian-American/Pacific Islander)
  • MENA (Middle Eastern/North African)
  • White/Caucasian
  • Race/Racial
  • Bias
  • Disparities/Disparity/ Disparate/Parity
  • Socioeconomic
  • Equity
  • Diverse/Diversity
  • Unequal
  • Equality
  • Equal
  • Income
  • Gender
  • Inclusion
  • Status


The keywords should be terms not already included in the title or abstract. Should your manuscript be accepted, the keywords will appear with the published manuscript, making it easier to find in literature search engines such as PubMed.

We encourage following the SAGER guidelines for sex and gender reporting. Regarding the abstract, if only one sex is included in the study, or if the results of the study are to be applied to only one sex or gender, the title and the abstract should specify the sex of animals or any cells, tissues and other material derived from these and the sex and gender of human participants.

What You Need to Know
All revised original research submissions and reviews must include text for a "What You Need to Know" box to appear on the second page of the published article. The text should include and relate to the following three headings:
  • Background
  • Findings
  • Implications for patient care


Please provide 1-2 sentences (25-30 words) under each of these three headings that succinctly summarize your study in relation to each category. This text should not include nonstandard abbreviations. Please upload this content in a single Word document file, separate from other manuscript materials.

Body of paper
Describe ethical guidelines followed; cite approval of institutional human research review committee or animal welfare committee; describe in detail hazardous procedures or chemicals involved, including precautions observed.

Outline statistical methods used.

Identify drugs and chemicals used by generic name (if trademarks are mentioned, manufacturer name and city are given).

All gene and protein names must be written according to NCBI or HUGO nomenclature. Official NCBI gene full names and symbols are preferred, although "Other Aliases" will be accepted. The Editors acknowledge that exceptions to these guidelines exist, and these will be considered on a case-by-case basis.

Introduction
We encourage following the SAGER guidelines for sex and gender reporting. Regarding the introduction, authors should report, where relevant, whether sex and/or gender differences may be expected.


Methods
We encourage following the SAGER guidelines for sex and gender reporting. Regarding the Methods, authors should report how sex and gender were taken into account in the design of the study, whether they ensured adequate representation of males and females, and justify the reasons for any exclusion of males or females.


Results
We encourage following the SAGER guidelines for sex and gender reporting. Regarding the Results, where appropriate, data should be routinely presented disaggregated by sex and gender. Sex- and gender-based analyses should be reported regardless of positive or negative outcome. In clinical trials, data on withdrawals and dropouts should also be reported disaggregated by sex.


Discussion
We encourage following the SAGER guidelines for sex and gender reporting. Regarding the discussion, the potential implications of sex and gender on the study results and analyses should be discussed. If a sex and gender analysis was not conducted, the rationale should be given. Authors should further discuss the implications of the lack of such analysis on the interpretation of the results.


References
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Cite references in order of appearance in text using superscripted Arabic numerals. Cite personal communications and unpublished data directly in text without being numbered. All abbreviations should follow the Index Medicus abbreviations. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article. Follow TIGE requirements for style:

Article (list 3 authors followed by et al): 13. Meltzer SJ, Ahnen DJ, Battifour H, et al. Protooncogene abnormalities in colon cancers and adenomatous polyps. Gastroenterology 1987;92:1174-1180.

Book: 18. Day RA. How to write and publish a scientific paper. Philadelphia: Institute for Scientific Information, 1979.

Article in Book: 22. Costa M, Furness JB, Llewellyn-Smith IF. Histochemistry of the enteric nervous system. In: Johnson LR, ed. Physiology of the gastrointestinal tract. Volume 1. 2nd ed. New York: Raven, 1987:1-40.

Dataset: 5. Oguro M, Imahiro S, Saito S, et al. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. http://dx.doi.org/10.17632/xwj98nb39r.1.

Tables
Tables should be prepared without the use of tabs; most table editor programs can be uploaded successfully. If your table contains decimal fractions, please round your numbers to two places after the decimal point. Tables may be embedded in the file that contains your manuscript or attached as separate files. Please spell out all abbreviations used in the table in an accompanying footnote.

Videos
  • All videos must be of the highest quality possible. Any editing of the video is the responsibility of the author(s).
  • Narration must be included with the video and is the responsibility of the author(s). Please be sure that all audio is at an appropriate level to be understood using computer speakers at mid-level volume.
  • No editing of the original data in individual frames or alteration of the original speed of the video can be made unless clearly stated.
  • Transitions should be selected in a consistent and simple pattern. Dramatic transitions are discouraged as they tend to distract the viewers from the main contents of the video.
  • Allow adequate pauses for the viewers to properly take in the information presented. A typical pause should be 4 -5 seconds long.
  • Acceptable video file formats are: MPEG (.mpg), Quicktime (.mov), or Microsoft (.avi).
  • Maximum video length is 3 minutes. Maximum file size/video is 160 MB.
  • No more than 6 videos per submission (unless otherwise noted).
  • Concise legends must accompany each video in the text file.
  • Patients should not be identifiable, or their pictures must be accompanied by written permission to use the video
  • Histology and/or radiology can be included for teaching purposes.


Figures
Images: Images can be clinical, pathologic (gross or microscopic), endoscopic, or radiographic. They should be of high quality (300 PPI or greater, clear, and in good focus) and illustrate the diagnosis well.

Photographs: Remove all names and all other patient identifiers from photos and radiographic studies.

Line Art and Graphs: Please be sure that any graphs or line art you submit are at a resolution of at least 300 PPI so that they are readable to reviewers.

Figure Legends: Please do not embed or flatten the text into the image files. Figure legends should be included in the manuscript body, immediately before the references.

Gel Electrophoresis Labels: Protein molecular weight or DNA marker sizes must be indicated on all figure panels showing gel electrophoresis.

Preferred Figure File Formats: The preferred formats for figure files are tiff (.tif) and jpeg (.jpg).

Accepted Figure File Formats: Other acceptable file formats include: .bmp, .gif, .pbm, .pcx, .png, .pct, .msp, .tif, .eps, .xbm, .psd, .ai, .indd, .pdf, and .tga files. When sending image files, please do not embed them in Word. You may submit mixed file formats (image1.jpg, image2.tif, image3.eps, etc.).

Image File Formats NOT Supported at this Time: Microsoft Word, Microsoft PowerPoint, Microsoft Excel Spreadsheets, ChemDraw, CorelDraw, Canvas, FreeHand, SigmaPlot, QuarkXpress, and Equation Editor. You may export image files from these programs as PDF, JPEG, or other acceptable file formats.

File Naming Convention: Figures should be named consecutively such as "figure 1.tif," "figure 2.jpg," etc., with the file extension appended (.tif, .jpg, .eps, etc). Each figure should be saved as a separate electronic file.

Color Files: Figures should be submitted in the CMYK color space. Authors are encouraged to present color figures in a manner that will allow the data to be interpreted by colorblind readers. TIGE suggests that authors present dual-labeled images in green and magenta rather than in green and red. See the website of the Jfly data depository for Drosphila researchers (http://jfly.iam.u-tokyo.ac.jp/color/ ) for more information on how to make figures and presentations intelligible for a colorblind audience.

Font: If your figures include text, an 8 to 10 point Arial font should be used. Acceptable fonts are "sans serif" fonts such as Helvetica, Arial, and Myriad. Examples of unacceptable fonts ("serif" fonts) are Times New Roman, Palatino, and Garamond. Lettering should begin with an upper case letter, followed by lower case lettering.

Multiple Panel Figures: Please submit each panel (image) separately. However, you may submit a multiple panel version to suggest the order in which you would like the panels arranged. You may also include a written, suggested layout. Each individual panel should be of the highest possible quality (300 DPI or higher) at actual print size.

Supplemental files
We encourage you to submit non-essential figures or portions of your manuscript as supplementary material for online-only publication, as our readership highly values supplementary materials. However, please note that the following items MUST be within the main text and not provided as supplemental information: 1) important materials and methods 2) references cited in the main text. Also, authors who offer supplementary information must ensure those materials are readily available upon request.

The portions of your manuscript that you would like to be included as supplementary material (including figures and tables) should be uploaded separately from the manuscript as "supporting documents." The supplementary material will not appear in the PDF, though there will be a link to access the file in the PDF of your submission.

Graphics Support
Authors are responsible for creating figures and videos (if they so choose) and for obtaining permission to use any images that they include from outside sources, including articles, web pages, stock photo sites or Google image searches. Any needed permissions must be submitted along with your graphical abstract or identified in the Acknowledgements section of your manuscript. The editorial office will not edit or narrate any videos.


Our medical illustration team has created an animation to show authors how they can create high-quality figures for their manuscripts. Authors can learn about our journals' style and better understand how to maximize the visual impact of the figures they create. Watch now!

DATA TRANSPARENCY
TIGE is committed to supporting the transparency, openness and reproducibility of science; to that end, the journal supports research data deposit and citation. Authors are encouraged to deposit their research data in a relevant data repository and cite these datasets in their articles.

REPORTING CLINICAL TRIALS

Registration
In according with the guidelines set for by the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/), authors of manuscripts involving clinical trials must provide full registration of their clinical trial(s). A clinical trial is defined as any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. The trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration.

Appropriate online registries include http://www.clinicaltrials.gov, http://www.isrctn.org, http://www.umin.ac.jp/ctr/index.htm, http://www.anzctr.org.au/, http://www.trialregister.nl or any primary registers that participate in the World Health Organization's International Clinical Trial Platform.

The clinical trial registry web site and the clinical trial number must be included at the end of the Conclusions section in the abstract (this information will not count toward the 260 word limit). Example: ClincialTrials.gov, number NCT002209456. This information must also be provided in the manuscript management system upon submission.

Randomized Controlled Trials
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on http://www.consort-statement.org. Manuscripts that fail to comply with CONSORT guidelines will not be reviewed for publication.

Access to Study Data
In the methods section, a statement must be made that all authors had access to the study data and had reviewed and approved the final manuscript.

MANUSCRIPT PROCESSING AND REVIEW

Submissions. Each new manuscript receives a unique number, and information on the manuscript is recorded on the Editorial Office computer network. The editorial staff releases information on manuscripts only to authors. The Editorial Office will e-mail a letter to the corresponding author acknowledging receipt of a manuscript, whether new or a resubmission. All manuscripts should be submitted online at https://www.editorialmanager.com/ytgie.

Review process. Each manuscript is reviewed initially by the Editors-in-Chief. If the quality is sufficient and scope appropriate, manuscripts are assigned to an Associate or Guest Editor who has expertise on the subject of the manuscript. After review by the Associate/Guest Editor, if the manuscript is judged to be appropriate and competitive for publication in TIGE, it is sent to experts in the appropriate area for external peer review. The Associate/Guest Editor chooses at least two reviewers, who remain anonymous. Authors are encouraged to suggest an Associate/Guest Editor and three to four reviewers in the cover letter, though final assignments are at the discretion of the Associate/Guest Editor.

Reviewers provide comments for the Editors and for the authors. The Journal expects reviewers to treat manuscripts as confidential communications and not to use the content for their own purposes or make copies of the manuscripts. Reviewers are also expected to declare to the editor any possible conflicts of interest.

The Associate/Guest Editor considers the reviewer comments and renders a preliminary decision, which is in turn evaluated, modified, and/or confirmed by the Editors-in-Chief. Manuscripts are either accepted or undergo revision via the same process described above until the manuscript is deemed appropriate for publication or rejected.

Decisions. The single most important criterion for acceptance is the originality of the work. However, a decision to accept a manuscript is not based solely on the scientific validity of its content. Other factors affecting decisions include the extent and importance of new information in the paper compared with that in other papers being considered, the Journal's need to represent a wide range of topics, and the overall suitability for TIGE. Decision letters usually, but not always, convey all factors considered for a particular decision. Occasionally, the comments to the authors may appear to be inconsistent with the editorial decision, which takes into consideration reviewers' comments to the editor, as well as the additional factors listed above.

APPEALS POLICY

The AGA values the opinions of its editors and reviewers and strongly discourages appeals, however if you believe your submission was rejected because the editors misunderstood it or there was unethical conduct in the peer-review process, you may submit an appeal. Please note the AGA journals do not accept appeal requests for manuscripts that were not externally peer reviewed.
  • Your appeal request will be processed by the TIGE managing editor. The appeal request will then be considered by the journal's editors-in-chief, who may seek input from the original submission's associate editor.
  • If the reason you are submitting an appeal is complex and requires an objective third-party evaluation, your appeal will instead be reviewed by the chair of the AGA Publications Committee and the relevant editorial staff.
  • There are several outcomes that could arise from your appeal request, including an invitation to revise, the upholding of the original decision, or an alternate course of action.
  • The editorial office will aim to provide the results of your appeal request back to you within two weeks, however there may be variation based on the complexity of the appeal. Please note that all decisions arising from an appeal request are considered final.


PUBLICATION

We will forward your unedited manuscript to our publisher for posting to the (Articles in Press) section of our web site. Your article should be posted within 2-3 days of receipt of files.

The publisher will forward page proofs to you for your final review within 4-6 weeks. The final version of your paper will be published online once proof corrections have been received.

For a complete list of rights you retain as author, click here.

There is a press embargo for all studies published in TIGE until they are posted online in our Articles in Press section as the paginated author-corrected proof in an "in progress" issue. Studies cannot be publicized as accepted manuscripts or uncorrected proofs. Please forward your acceptance email to your institution press officer for promotional consideration. We ask that your PR contacts share promotion plans and/or address any questions to media@gastro.org.

Manuscripts are copyedited to make them consistent with Journal style. If a particular section in the manuscript is not clear or requires additional information, the copy editor will direct questions to the author. These questions, or "author queries," will appear in the proofs that are sent to the author. Authors are required to return proofs to the publisher within 48 hours. If changes are not returned within 48 hours, the manuscript will move forward in the production process.

Licensing Options

TIGE offers authors the choice of different forms of Creative Commons licenses that will allow others to make use of the published work. Authors must select the type of license at the time of submission. An overview of these licenses is included below. For more detailed information, please go to https://www.elsevier.com/openaccesslicenses.

Creative Commons Attribution-NonCommercial-NoDerivs (CC-BY-NC-ND): Allows others to access and download an article and share it with others as long as they credit the author (and do not represent the author as endorsing their work), but they cannot change the article in any way or use it commercially.

COMMERCIAL SPONSORSHIPS/SUPPLEMENTS

TIGE does not currently offer commercial sponsorships or release supplements.

EDITORIAL OFFICE

The address for correspondence is: Vinay Chandrasekhara, MD, Michael Kochman, MD, AGAF, Co-Editors, Techniques and Innovations in Gastrointestinal Endoscopy, AGA Institute, 4930 Del Ray Avenue, Bethesda, Maryland 20814-3015; e-mail: tige@gastro.org; tel: 301-941-9781.
Advertisement